Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Albert Labs International Corp C.ABRT

Healthcare Biotechnology
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.

Recent & Breaking News (CSE:ABRT)

CSE Bulletin: Suspensions - ABRT, JUVA, LITE, VSBY, VSBY.WT.B

Newsfile July 16, 2024

Canadian Investment Regulatory Organization Trading Halt - ABRT

Canada NewsWire July 16, 2024

CSE Bulletin: Reinstatement - Albert Labs International Corp. (ABRT)

Newsfile July 7, 2023

Canadian Investment Regulatory Organization Trade Resumption - ABRT

Canada NewsWire July 7, 2023

CSE Bulletin: Suspensions - ADMT, ABRT, CFT, GAIA, IWIN, PKG, POLE, PRTI, RWB, CALM, RVR, VEJI

Newsfile May 9, 2023

IIROC Trading Halt - ABRT

Canada NewsWire May 9, 2023

Albert Labs Receives preliminary acceptance of 35 Novel Inventive Claims for Patent Protected Manufacturing Technology

Canada NewsWire May 2, 2023

Albert Labs announces Private Placement

Canada NewsWire April 24, 2023

Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human Trials

Canada NewsWire March 28, 2023

Albert Labs Validates Global Supply Chain for Controlled Substances

Canada NewsWire March 15, 2023

Albert Labs signs Letter of Intent (LOI) with iNGENū CRO for First In-Human Clinical Studies

Canada NewsWire November 17, 2022

Albert Labs provides Corporate Update

Canada NewsWire October 25, 2022

Albert Labs Files New International PCT Patent Application for scalable API manufacturing

Canada NewsWire October 20, 2022

Albert Labs Appoints Two Industry Leading Directors

Canada NewsWire July 11, 2022

Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101

Canada NewsWire May 26, 2022

Albert Labs Granted Health Canada Licence

Canada NewsWire May 16, 2022

Albert Labs' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming Studies

Canada NewsWire May 12, 2022

Albert Labs Announces the Addition of Two Renowned Scientific Advisors to its Scientific Advisory Board (SAB)

Canada NewsWire April 26, 2022

Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia

Canada NewsWire March 30, 2022

Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the Canadian Securities Exchange

Canada NewsWire March 10, 2022

Podcasts